DCA10 CRSP-CVD-400 - Clinical Trial

¿Quién puede participar en el Estudio?

Grupo etario

Adultos

Detalles del Estudio

Título Completo

DCA10: A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

Investigador Principal